Neurocrine Biosciences (NBIX) Inventory Average (2017 - 2026)

Neurocrine Biosciences (NBIX) has reported Inventory Average for 10 consecutive years, with $84.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory Average rose 45.43% year-over-year to $84.4 million; the trailing twelve-month figure through Jun 2026 stood at $84.4 million (up 45.43% YoY), and the FY2025 full-year result was $63.2 million, up 32.08% from the prior year.
• Inventory Average rose to $84.4 million in Q2 2026 per NBIX's latest filing, from $66.8 million in the prior quarter.
• Across five years, Inventory Average topped out at $84.4 million in Q2 2026 and bottomed at $29.2 million in Q2 2022.
• Historically, Inventory Average has averaged $46.2 million across 5 years, with a median of $38.8 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Inventory Average declined 8.75% in 2023, then soared 54.3% in 2025.
• Over 5 years, Inventory Average stood at $36.0 million in 2022, then slipped by 6.93% to $33.6 million in 2023, then soared by 53.8% to $51.6 million in 2024, then surged by 34.01% to $69.1 million in 2025, then climbed by 21.98% to $84.4 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $84.4 million, $66.8 million, and $69.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.